Catalog No.
AHC00101
Biological activity
Measured by its binding ability in a functional ELISA. When recombinant human CD32A/FCGR2A is immobilized at 2 µg/mL (100 µL/well), the concentration of recombinant human APCS/SAP (Cat #: AHC00101) that produces 50% of the optimal binding response is 0.175-1 μg/mL.
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
His20-Val223
Nature
Recombinant
Endotoxin level
<0.1 EU/μg of the protein by the LAL method.
Purity
>90% as determined by SDS-PAGE.
Accession
P02743
Applications
Bioactivity, ELISA, Immunogen, SDS-PAGE, WB
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 5% Trehalose, 5% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for one week. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
APCS, PTX2, Serum amyloid P-component, 9.5S alpha-1-glycoprotein, SAP, Pentraxin 2, Pentraxin-2
Exploring anti-SARS-CoV-2 natural products: dual-viral target inhibition by delphinidin and the anti-coronaviral efficacy of deapio platycodin D., PMID:40512442
Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies., PMID:40503878
Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates., PMID:40498855
Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection., PMID:40498720
Long COVID-19 autoantibodies and their potential effect on fertility., PMID:40496870
SARS-CoV-2 exploits steroidogenic machinery, triggers lipid metabolism for viral replication and induces immune response in Leydig cells of K18-hACE2 mice., PMID:40496014
Is SARS-CoV-2 facing constraints in its adaptive evolution?, PMID:40495805
Convergent Evolution of Two Dopamine Receptor Genes: Repeated Evolution of Exon 6 Skipping in Drd2, and Repeated Deletion of Exon 6 in Drd3., PMID:40488893
The effect of early COVID-19 treatment with convalescent plasma on antibody responses to SARS-CoV-2., PMID:40488473
Expression of a constitutively active nitrate reductase increases SARS-CoV-2 Spike protein production in Nicotiana benthamiana leaves that otherwise show traits of senescence., PMID:40483589
Single-particle quantification of SARS-CoV-2 virus-like particles using flow virometry., PMID:40483334
Immune age is correlated with decreased TCR clonal diversity and antibody response to SARS-CoV-2., PMID:40481111
Influence of Cholesterol on the Insertion and Interaction of SARS-CoV-2 Proteins with Lipid Membranes., PMID:40474679
No evidence of immune exhaustion after repeated SARS-CoV-2 vaccination in vulnerable and healthy populations., PMID:40473598
Identification of substrates and sequence requirements for CARNMT1-mediated histidine methylation of C3H zinc fingers., PMID:40473212
Comparing models and experimental structures of the GPR101 receptor: Artificial intelligence yields highly accurate models., PMID:40472416
Serum Levels of IL-21 and IL-27 Do not Reflect differential Avidity of Anti-SARS-CoV-2 IgG Antibodies in Symptomatic and Asymptomatic COVID-19 Patients., PMID:40471646
Fc-effector functional antibody assays for SARS-CoV-2 variants of concern., PMID:40463385
Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccines., PMID:40463102
Seroprevalence Trends of Antibodies to SARS-CoV-2 in South Korea, 2021-2022: A Repeated Cross-Sectional Study., PMID:40462400
SARS-CoV-2-specific humoral immunity in a Norwegian cohort between 2020 and 2023., PMID:40462062
Wastewater dataset on the SARS-CoV-2 sublineages circulating in Central Arkansas, USA, post-COVID-19 pandemic., PMID:40461497
Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response., PMID:40461490
Unveiling the structural spectrum of SARS-CoV-2 fusion by in situ cryo-ET., PMID:40461447
Tracking the dynamics of antibody production against the SARS-CoV-2 virus after two doses of the mRNA vaccine BNT162b2., PMID:40461246
Multi-level inhibition of SARS-CoV-2 invasion by cannabidiol and epigallocatechin gallate., PMID:40460494
Computational design of therapeutic antibodies with improved developability: efficient traversal of binder landscapes and rescue of escape mutations., PMID:40458889
Addressing SARS-CoV-2 evolution: neutralization of emerging variants of concern by the AVX/COVID-12 'Patria' vaccine based on HexaPro-S ancestral Wuhan spike or its updated BA.2.75.2 version., PMID:40458417
Mapping of human monoclonal antibody responses to XBB.1.5 COVID-19 monovalent vaccines: a B cell analysis., PMID:40456237
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base., PMID:40447603
Multiplex ACE2-RBD binding inhibition assay: An integrated tool for assessing neutralizing antibodies to SARS-CoV-2 variants and protection against breakthrough infections., PMID:40447072
Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota., PMID:40444030
Broad-spectrum coronavirus inhibitors discovered by modeling viral fusion dynamics., PMID:40443526
ACE2, a therapeutic target of COVID-19, needs to be treated with caution., PMID:40439840
Sulfonohydrazide as a potential inhibitor of SARS-CoV-2 infection., PMID:40437072
Systems serology-based comparison of humoral immune responses induced by liposome or aluminum hydroxide adjuvanted SARS-CoV-2 spike protein., PMID:40436929
Neutralizing antibody levels as a key factor in determining the immunogenic efficacy of the novel PEDV alpha coronavirus vaccine., PMID:40432512
A Luciferase-Based Approach for Functional Screening of 5' and 3' Untranslated Regions of the mRNA Component for mRNA Vaccines., PMID:40432139
A Novel Antiviral Therapeutic Platform: Anchoring IFN-β to the Surface of Infectious Virions Equips Interferon-Evasive Virions with Potent Antiviral Activity., PMID:40431708
Receptor Binding for the Entry Mechanisms of SARS-CoV-2: Insights from the Original Strain and Emerging Variants., PMID:40431702
Impact of Vaccine-Elicited Anti-Spike IgG4 Antibodies on Fc-Effector Functions Against SARS-CoV-2., PMID:40431678
Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year., PMID:40431652
SARS-CoV-2 Spike Protein and Long COVID-Part 2: Understanding the Impact of Spike Protein and Cellular Receptor Interactions on the Pathophysiology of Long COVID Syndrome., PMID:40431631
SARS-CoV-2 Spike Protein and Long COVID-Part 1: Impact of Spike Protein in Pathophysiological Mechanisms of Long COVID Syndrome., PMID:40431629
Isolation and Characterization of Porcine Epidemic Diarrhea Virus G2c Strains Circulating in China from 2021 to 2024., PMID:40431537
The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil., PMID:40430765
Evaluating SARS-CoV-2 T Cell Immunity in COVID-19-Naive Vaccinated Individuals with and Without Spike Protein IgG Antibodies., PMID:40430736
Efficient Searches in Protein Sequence Space Through AI-Driven Iterative Learning., PMID:40429882
Rapid and Cost-Effective Diagnostic Blot Assays Based on the Use of Plant-Produced Recombinant Antigens: Lessons Learned from the SARS-CoV-2 RBD Antigen., PMID:40429644
Integrative Genomic and in Silico Analysis Reveals Mitochondrially Encoded Cytochrome C Oxidase III (MT-CO3) Overexpression and Potential Neem-Derived Inhibitors in Breast Cancer., PMID:40428367
For research use only. Not for human or drug use.
